14
November 2024
Assura plc
Confirmation of secondary
listing on the Johannesburg Stock Exchange
Assura plc ("Assura" or the
"Company"), the UK's leading diversified healthcare REIT, is
pleased to confirm that the Johannesburg Stock Exchange ("JSE") has
granted approval to Assura for a secondary listing on the Main
Board of the JSE. The commencement of trading is expected to take
effect on Thursday, 21 November 2024.
The Company has released a
pre-listing announcement ("PLA") in relation to a secondary inward
listing on the Main Board of the JSE by way of an
introduction.
Assura continues to see
opportunities in providing critical healthcare infrastructure and
believes that this secondary listing will provide a new potential
pool of capital to fund the Company's continued growth.
In particular, the listing will
enable Assura to:
·
give South African investors a local platform to
more easily invest in and trade Assura shares;
·
broaden the Company's shareholder base with new
South African investors;
·
increase liquidity for shareholders;
and
·
diversify the Company's shareholder base and
position it for future growth.
The Company will not place or issue
any new Assura shares in connection with its application for a
secondary listing on the JSE and will remain listed on the Equity
Shares (Commercial Companies) category (ESCC) of the Official List
in London.
HSBC is acting as Listing
Co-ordinator and Corporate Broker and Nedbank Corporate and
Investment Banking, a division of Nedbank Limited, as Corporate
Advisor and JSE Sponsor.
Jonathan Murphy, CEO, said:
"We are delighted that our secondary
listing on the Johannesburg Stock Exchange, which we believe will
contribute to liquidity in our shares, has been
approved.
As the UK's leading diversified
healthcare REIT, Assura offers an attractive proposition to South
African investors. We look forward to welcoming them onto our share
register. Our high quality assets offer long-term secured and
growing income, underpinned by the long-term structural demand for
healthcare services."
- Ends
-
For more information, please
contact:
|
Assura plc
|
Tel: 0161 515 2043
|
|
David Purcell, Investor Relations
Director
|
Email: Investor@assura.co.uk
|
|
FGS Global
Gordon Simpson
Grace Whelan
|
Tel: 0207 251
3801
Email: Assura@fgsglobal.com
|
|
HSBC Bank Plc
Chloe Ponsonby
Jonathan Surr
Louis Davies
|
Tel: 020
7991 8888
|
Notes to Editors
Assura plc is
the UK's leading diversified healthcare REIT. Assura
enables better health outcomes through its portfolio of more than
600 healthcare buildings, from which over six million patients are
served.
A UK REIT based
in Altrincham, Assura is a constituent of the FTSE 250 and the
EPRA* indices. As at 30 September 2024, Assura's portfolio was
valued at £3.2 billion and has a strong track record of
growing financial returns and dividends for
shareholders.
At Assura, we BUILD for health,
having developed over 100 new healthcare buildings in our history,
and at the heart of our strategy sits The Bigger Picture; Healthy
Environment (E), Healthy Communities (S), Healthy Business
(G).
Further information is available
at www.assuraplc.com
*EPRA is a
registered trademark of the European Public Real Estate
Association